BiotechTube

ONO-5046Na + ONO-5046Na

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Community-acquired Pneumonia

Conditions

Community-acquired Pneumonia

Trial Timeline

Dec 1, 2006 → —

NCT ID
NCT00417326

About ONO-5046Na + ONO-5046Na

ONO-5046Na + ONO-5046Na is a phase 2 stage product being developed by Ono Pharmaceutical for Community-acquired Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT00417326. Target conditions include Community-acquired Pneumonia.

What happened to similar drugs?

1 of 8 similar drugs in Community-acquired Pneumonia were approved

Approved (1) Terminated (0) Active (7)
✅IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved
🔄Ceftaroline + CeftriaxonePfizerPhase 3
🔄Azithromycin microspheres 2.0 single dosePfizerPhase 3
🔄Azithromycin SRPfizerPhase 3
🔄tigecyclinePfizerPhase 3
🔄Tigecycline + LevofloxacinPfizerPhase 3
🔄Omadacycline + MoxifloxacinZai LabPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00417326Phase 2Completed

Competing Products

9 competing products in Community-acquired Pneumonia

See all competitors
ProductCompanyStageHype Score
Ceftaroline + CeftriaxonePfizerPhase 3
40
Azithromycin microspheres 2.0 single dosePfizerPhase 3
40
IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacinPfizerApproved
43
Azithromycin SRPfizerPhase 3
40
Azithromycin SR + AmoxiclavPfizerPre-clinical
18
tigecyclinePfizerPhase 3
40
Tigecycline + LevofloxacinPfizerPhase 3
40
Omadacycline + MoxifloxacinZai LabPhase 3
41
ceftobiprole medocaril + IV standard-of-care cephalosporinBasilea PharmaceuticaPhase 3
34